Howard Financial Services LTD. Acquires 509 Shares of Eli Lilly and Company $LLY

Howard Financial Services LTD. grew its holdings in Eli Lilly and Company (NYSE:LLY) by 43.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,693 shares of the company’s stock after buying an additional 509 shares during the period. Howard Financial Services LTD.’s holdings in Eli Lilly and Company were worth $2,030,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC raised its holdings in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. grew its position in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC acquired a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $356,000. Finally, Nebula Research & Development LLC bought a new position in shares of Eli Lilly and Company during the second quarter worth approximately $749,000. 82.53% of the stock is currently owned by institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA granted Breakthrough Therapy designation to Lilly’s investigational KRAS G12C inhibitor olomorasib for previously treated patients with advanced pancreatic cancer. The designation may accelerate development and regulatory interaction for a potential new oncology revenue stream. Lilly’s olomorasib receives FDA Breakthrough Therapy designation
• Positive Sentiment: Lilly is collaborating with Amplia Therapeutics to test olomorasib with narmafotinib in a Phase 1b/2b trial for advanced non-small cell lung cancer. The combination could expand olomorasib’s potential use beyond pancreatic and other cancers, although it remains an early-stage opportunity. Amplia collaboration with Lilly on olomorasib trial
• Positive Sentiment: Lilly will allow a limited number of patients to seek special access to experimental obesity drug retatrutide before potential FDA approval. The move highlights demand for the next-generation therapy and keeps attention on Lilly’s obesity pipeline. Lilly to offer early access to retatrutide
• Neutral Sentiment: Lilly’s upcoming earnings report is the immediate focus. Investors will look for continued prescription and revenue momentum from Mounjaro and Zepbound, management’s outlook, and updates on manufacturing capacity and pricing. Will Mounjaro and Zepbound drive Lilly’s Q2 results?
• Negative Sentiment: Investor expectations are elevated after Lilly’s powerful multiyear rally and roughly $1 trillion-plus valuation. Valuation analyses question whether projected cash flows justify the current price, increasing downside risk if earnings or guidance fall short. Eli Lilly stock looks below fair value on cash flow
• Negative Sentiment: Competition in the obesity-drug market remains a concern, as Novo Nordisk is attempting to regain ground. Any evidence of slowing demand, pricing pressure or improved rival products could challenge Lilly’s premium growth expectations. Obesity battle heats up between Novo and Lilly

Analysts Set New Price Targets

LLY has been the subject of several recent research reports. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Guggenheim increased their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, Sanford C. Bernstein upped their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,115.68 on Wednesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock’s 50-day simple moving average is $1,154.75 and its 200 day simple moving average is $1,044.52. The firm has a market capitalization of $1.05 trillion, a PE ratio of 39.63, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.